HER3-DXd
Lung Cancer
Patritumab deruxtecan (HER3-DXd; MK-1022) in non–small cell lung cancer after platinum-based chemotherapy and immunotherapy
Steuer CE, Hayashi H, Su W-C, et al.
J Clin Oncol. 2025;0,24-02744
Other/Multi
Breast Cancer
Patient preferences for treatments in hormone receptor-positive/HER2-negative metastatic breast cancer in Italy: A discrete choice experiment study
Arpino G, De Angelis C, Gerratana L, et al.
BMC Cancer. 2025 May 22;25(1):920. doi: 10.1186/s12885-025-14308-4.
T-DXd
Gastric Cancer
Trastuzumab deruxtecan or ramucirumab plus pacitaxel in gastric cancer
Shitara K, Van Cutsem E, Gümüş M, et al.
N Engl J Med. 2025 May 31. doi: 10.1056/NEJMoa2503119. Epub ahead of print
Pexidartinib
Other/Multi
TURALIO® risk evaluation and mitigation strategy (tREMS) program: 5-year retrospective hepatic safety assessment
Waheed Rajper A, Dharmani C, Chilakapati L, Fofah O, Wooddell MJ
Future Oncol. 2025 May 29:1-7. doi: 10.1080/14796694.2025.2509409. Epub ahead of print.
HER3-DXd
Breast Cancer Colorectal Cancer Lung Cancer
Integrated two-analyte population pharmacokinetics model of patritumab deruxtecan (HER3-DXd) monotherapy in patients with solid tumors
Xu Y, Lee M, Joshi R, et al.
Clin Pharmacokinet. 2025 May 23. doi: 10.1007/s40262-025-01521-4. Epub ahead of print.
Dato-DXd
Breast Cancer
TROPION-Breast05: A randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer
Schmid P, Oliveira M, O'Shaughnessy J, et al.
Ther Adv Med Oncol. 2025 Apr;17:17588359251327992. doi: 10.1177/17588359251327992.
Valemetostat
Hematology
Effect of mild to moderate hepatic impairment on valemetostat pharmacokinetics: An open-label, phase I study
Tachibana M, Craveiro TV, Marbury TC, et al.
Clin Pharmacol Drug Dev. 2025 May 14. doi: 10.1002/cpdd.1544. Epub ahead of print.
T-DXd
Breast Cancer
Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: Results from the randomized DESTINY-Breast06 trial
Hu X, Curigliano G, Yonemori K, et al.
ESMO Open. 2025 May 14; 105082. doi: 10.1016/j.esmoop.2025.105082. Epub ahead of print
T-DXd
Breast Cancer
Patient-reported outcomes from DESTINY-Breast04: Trastuzumab deruxtecan versus physician’s choice of chemotherapy in patients with HER2-low mBC
Ueno NT, Cottone F, Dunton K, et al.
Oncologist. 2025 May 8;30(5):oyaf048. doi: 10.1093/oncolo/oyaf048.
Quizartinib
Hematology
Synergistic activity of combined FLT3-ITD and MDM2 inhibition with quizartinib and milademetan in FLT3-ITD mutant/TP53 wild type acute myeloid leukemias
Zhang W, Li L, Muftuoglu M, et al.
Clin Cancer Res. 2025 May. doi: 10.1158/1078-0432.CCR-24-2764. Epub ahead of print.
Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26